多发性骨髓瘤序贯靶向:GPRC5D双特异性抗体talquetamab作为BCMA CAR-T治疗的桥接
多中心回顾性分析评估talquetamab作为桥接治疗用于接受cilta-cel或ide-cel的复发/难治多发性骨髓瘤患者,134例中119例成功桥接至CAR-T,talquetamab缓解率71%,桥接后CAR-T缓解率88%,毒性可控,提示桥接安全可行。
要点
- 134例接受talquetamab桥接,119例后续接受CAR-T(cilta-cel 98例,ide-cel 21例)。
- talquetamab缓解率71%,桥接后CAR-T缓解率88%(完全缓解54%)。
- 未发生≥3级细胞因子释放综合征,仅2%发生3级ICANS。
核心结论
- talquetamab桥接治疗似乎是安全的,使大多数难治患者能够成功接受BCMA CAR-T治疗。
研究设计与样本
- 多机构回顾性分析,覆盖20个中心(美国18个,德国2个)。
- 评估talquetamab作为桥接治疗用于后续cilta-cel或ide-cel的复发/难治多发性骨髓瘤患者。
- 共134例患者接受talquetamab,其中119例后续接受CAR-T(cilta-cel 98例,ide-cel 21例)。
主要发现
- 中位年龄65岁,中位既往治疗线数5线。
- 85%的患者不符合CARTITUDE-1/KarMMa入组标准。
- 15例未接受CAR-T的原因包括疾病进展(7例)、生产失败(6例)或患者决定(2例)。
- talquetamab中位给药23天,缓解率71%。
- talquetamab毒性:无≥3级CRS,2%发生3级ICANS;1-2级特有毒性包括口腔70%、皮肤38%、指甲17%,其中60%已缓解。
关键数值与推荐
- CAR-T后88%缓解(54%完全缓解),毒性低级别:2例≥3级CRS,1例3级ICANS,5%≥3级感染。
- 发生2例面神经麻痹和1例急性髓系白血病。
- talquetamab与持续性可溶性BCMA下降及CAR-T扩增峰值(约第14天)相关。
临床怎么用
- 原文结论认为talquetamab桥接治疗似乎是安全的,使大多数难治患者能够成功接受BCMA CAR-T治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), 2 B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapies, have transformed outcomes for relapsed/refractory multiple myeloma; however, the 6 to 8 weeks manufacturing time risks disease progression or death in up to 10% of patients. Talquetamab, a G-protein-coupled receptor, family C, group 5, member D (GPRC5D)-targeting bispecific antibody, represents a promising option. We performed a multi-institutional retrospective analysis across 20 centers (18 United States, 2 Germany) evaluating talquetamab as a bridging therapy prior to cilta-cel or ide-cel. Among 134 patients receiving talquetamab, 119 proceeded to CAR-T (n = 98 cilta-cel, n = 21 ide-cel). Reasons for not proceeding (n = 15) included progression (n = 7), manufacturing failure (n = 6), or patient decision (n = 2). Median age was 65 years and had median 5 prior lines of therapy. Notably, 85% would not have met CARTITUDE-1/KarMMa eligibility criteria. Talquetamab was administered for a median 23 days. Toxicity was manageable: no grade ≥3 cytokine release syndrome (CRS), 2% grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) and grade 1 to 2 talquetamab unique toxicities (70% oral, 38% skin, and 17% nail; 60% resolved). Talquetamab achieved 71% response rate. After CAR-T, 88% responded (54% complete response), with low-grade toxicities (2 grade ≥3 CRS, 1 grade 3 ICANS, and 5% grade ≥3 infections). Two cases of facial palsy and 1 acute myeloid leukemia occurred. Talquetamab correlated with sustained soluble BCMA decline and peak CAR-T expansion around day 14. Talquetamab bridging appears safe, enabling the majority of difficult-to-treat patients to successfully proceed to BCMA CAR-T therapy.
引用
- Dhakal B, Akhtar OS, Fandrei D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025. PMID: 40749169. doi:10.1182/blood.2025029773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。